An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
NCT ID: NCT05669794
Last Updated: 2025-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
300 participants
OBSERVATIONAL
2023-02-21
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Upadacitinib is an approved drug for treating AD. Approximately 300 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in France.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
NCT05139836
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882
An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
NCT05394792
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
NCT03607422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Upadacitinib
Participants will receive upadacitinib as prescribed by their physician according to local label.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptom onset ≥1 year prior to baseline.
* Initiation of upadacitinib treatment for AD is indicated and prescribed per local label.
* The decision to prescribe upadacitinib is made prior to and independently of study participation.
* Participants who can understand and who are willing and able to complete the questionnaires, with parental support as required for adolescents.
* Participants (or legal representatives for adolescents) with a smartphone/tablet with internet access and willing to download the dedicated application to complete the questionnaires via this application.
* Participants (and legal representatives for adolescents) who have been informed verbally and in writing about this study before inclusion, and who do not object to their data being processed.
* Participants (and legal representatives for adolescents) able to understand and communicate with the investigator.
Exclusion Criteria
* Prior treatment with upadacitinib.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ch Saint Quentin /Id# 249270
Saint-Quentin, Aisne, France
CHU Clermont-Ferrand /ID# 248611
Clermont, Auvergne-Rhône-Alpes, France
Hôpital Européen Marseille /ID# 257643
Marseille, Bouches-du-Rhone, France
Hopital Saint Joseph /ID# 255537
Marseille, Bouches-du-Rhone, France
Hopital Ponchaillou /ID# 251225
Rennes, Brittany Region, France
CHU Dijon /ID# 248984
Dijon, Cote-d Or, France
CH Georges Renon /ID# 248976
Niort, Deux-Sevres, France
CHU de Besancon - Jean Minjoz /ID# 248642
Besançon, Doubs, France
Hopitaux Drome Nord /ID# 248207
Romans-sur-Isère, Drome, France
CH Valence /ID# 250693
Valence, Drome, France
Centre Hospitalier de Quimper /ID# 251119
Quimper, Finistere, France
CHU Montpellier - Hopital Saint Eloi /ID# 251877
Montpellier, Herault, France
CHU nord - hopital Felix Guyon /ID# 250694
Saint-Denis, Le Reunion, France
Centre Hospitalier Saint-Nazaire /ID# 251200
Saint-Nazaire, Loire-Atlantique, France
Polyclinique Courlancy /ID# 250476
Reims, Marne, France
Hopital du Scorff /ID# 251226
Lorient, Morbihan, France
CHR Metz-Thionville - Hopital Bel-Air /ID# 252267
Thionville, Moselle, France
Centre Hospitalier de Valenciennes /ID# 258642
Valenciennes, Nord, France
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 247209
Créteil, Paris, France
Hopitaux Universitaires Paris Centre-Hopital Cochin /ID# 250807
Paris, Paris, France
CHU de Nantes, Hotel Dieu -HME /ID# 262563
Nantes, Pays de la Loire Region, France
Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord /ID# 251117
St-Priest-en-Jarez, Pays de la Loire Region, France
HCL - Hopital Lyon Sud /ID# 248864
Pierre-Bénite, Rhone, France
Centre Hospitalier du Mans /ID# 250510
Le Mans, Sarthe, France
Centre Hospitalier Métropole Savoie - Site Hôpital de Chambéry /ID# 252012
Chambéry, Savoie, France
CH Pontoise - Hopital René Dubos /ID# 248843
Pontoise, Val-d Oise, France
CH Avignon /ID# 251198
Avignon, Vaucluse, France
CHI POISSY - Saint-Germain-en-Laye /ID# 248612
Saint-Germain-en-Laye, Yvelines, France
Hopital Nord Amiens /ID# 250300
Amiens, , France
Chu Angers /Id# 248674
Angers, , France
CH Victor Dupouy /ID# 247216
Argenteuil, , France
Centre Hospitalier de Béziers /ID# 264454
Béziers, , France
Hopital Ambroise Pare /ID# 253337
Boulogne-Billancourt, , France
CHU de CAEN - Hopital de la Cote de Nacre /ID# 252127
Caen, , France
CH de Cahors /ID# 251190
Cahors, , France
Centre Hospitalier de Calais /ID# 249449
Calais, , France
Cabinet Dermatologie et Esthetique /ID# 247972
Cannes, , France
CH William Morey /ID# 256417
Chalon-sur-Saône, , France
CH Annecy Genevois - Site Annecy /ID# 249024
Epagny Metz Tessy, , France
CH la Rochelle /ID# 252128
La Rochelle, , France
CH Emile Roux Le Puy en Velay /ID# 248983
Le Puy-en-Velay, , France
Hopital Saint Vincent de Paul /ID# 247218
Lille, , France
CHU Limoges - Dupuytren 2 /ID# 251224
Limoges, , France
Hopital Femme Mere Enfant /ID# 258682
Lyon, , France
Cideazur /ID# 247905
Nice, , France
Hôpital Saint-Louis /ID# 251228
Paris, , France
Cabinet libéral du Dr KURIHARA /ID# 249664
Paris, , France
Hopital Bichat-Claude Bernard /ID# 251274
Paris, , France
CH de PAU /ID# 248567
Pau, , France
Hôpital Charles-Nicolle /ID# 247215
Rouen, , France
CHU de Rouen /ID# 250648
Rouen, , France
Hôpital d'instruction des armées Bégin /ID# 247751
Saint-Mandé, , France
Ch Salon de Provence /Id# 248829
Salon-de-Provence, , France
Hôpital d'Instruction des Armées Sainte-Anne /ID# 247908
Toulon, , France
CHU Toulouse - Hopital Larrey /ID# 247219
Toulouse, , France
Hopital Nord Franche Comté /ID# 261628
Trévenans, , France
Cabinet Liberal /ID# 251195
Villeurbanne, , France
Hopital Prive d'Antony /ID# 247324
Antony, Île-de-France Region, France
Hopital Pitie Salpetriere /ID# 253464
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P23-628
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.